Concentrations of serum neopterin and homocysteine concentrations as well as pyridoxal-5-phosphate (P-5-P) deficiency have been determined in 30 healthy individuals and 61 patients with coronary heart disease (CHD) verified by coronary angiography. Patients have been observed before percutaneus trans luminal coronary angioplasty followed by balloon angioplasty (10 patients; group I), 1" time stent implantation (27 patients; group II) , repeated stent implantation (8 patients; group III) and due to restenosis (16 patients; group IV). An increase of serum homocysteine concentrations as well as P-5-P deficiency was observed in all groups of CHD patients , while elevated serum neopterin concentrations were identified only in CHD patients of groups III and IV i.e. mainly in patients presenting with serious coronary events. The grade of P-5-P deficiency and serum homocysteine concentrations was higher in patients with restenosis than in patients before the 1" time stent implantation, suggesting that both, normalization of P-5-P and of serum homocysteine concentrations could be significant in the prevention of CHD as well as in the treatment of CHD patients.
Introduction
Neopterin, a pteridine derivative, is secreted by macrophages upon stimulation with the cytokine interferon-? and is a sensitive marker for the activation of the cell-mediated immune system (1). Studies have reported an association between neopterin levels and the grade of atherosclerosis (2 ,3) . After the obsenration that homocysteine promotes vascular endothelial (4) and smooth muscle cell (5) growth, this amino acid has been proposed as a link to atherosclerosis development and progression. In 1981 we observed pyridoxal-5-phosphate (P-5-P) deficiency in many patiens with ischemic heart disease (6), later confirmed by others (7) . The aim of this study was to compare the significance of these 3 indices in patients with coronary heart disease (CHD).
Materials and Methods
In this study, 30 healthy individuals and 61 patients with CHD verified by coronary angiography were examined. All patients were observed before percutaneus trans luminal coronary angioplasty (PTCA) fo1-lowed by balloon angioplasty (10 patiens; group I), 1 st time stent implantation (27 patients; group II), repeated stent implantations (8 patiens; group III) and due to restenosis (16 patients; group IV). Serum concentrations of neopterin have been determined by radioimmunoassay (BRAHMS-Diagnostica, Berlin, Germany), and serum concentrations of homocysteine by the Abbott-Imx analyser (8) . P-5-P deficiency has been identified using 30 mg/kg L-t1yptophan peroral load test followed by the comparison of serum kynurenine concentl'ations at fasting state and 3 h after loading (9) . This method is based on the high sensitivity of kynureninase (L-kynurenine hydrolase; EC 3.7.1.3) to P-5-P deficiency (10, II).
Statistical comparisons of groups were performed using Student's t-test, for correlation analyses linear regression coefficients and Speamlan rank correlation coefficients were calculated. P values below 0.05 were considered to indicate statistical significance. concentrations in healthy individuals (controls) and in all groups of CHD patients. Elevation of mean neopterin concentrations was observed in groups III and IV of CHD patients (P < 0.001) if compared with controls, while increased mean homocysteine concentrations were found in all groups of CHD patients (P <0.01 -P <0 .001). There existed a significant association between higher neopterin and homoc ysteine concentrations (rs = 0.225 , P <0.05; n = 61).
Results
Mean kynurenine concentratios were also increased 
Discussion
An association has been reported between neopterin concentrations and the grade of atherosclerosis (2, 3) . Further studies suggest that neopterin may be a marker of coronary disease activity and identifies patients at increased risk of serious coronary events (12) . Our results of increased neopterin concentrations in CHD patients after repeated stent implantations (group III of CHD patients) and in cases of restenosis (group IV of CHD patients) partly affirm these earlier findings.
Homocysteine is an amino acid, which in mammals is formed from the essential amino acid methionine (13) and is cleaved to cysteine by P-S-P-dependent enzyme systems: cystationine-l3-synthase (EC 4.2.l.22) and cystathionase (EC 4.4.1.1) (14) . These studies explain both, earlier observed dependence of sulphur transport on pyridoxine (IS) and arteriosclerotic lesions found in pyridoxine-deficient monkeys (16) . Promotion of cholesterol precipitation by homocysteine is not proven yet, but it could be also induced by other metabolites which accumulate in biological fluids due to P-5-P deficiency, such as kynurenine, xanthurenic acid and so on (17) . P-5-P is a biologically active form of vitamin B6 (pyridoxine) and a lot of many enzyme systems depend on the presence of P-S-P (14) . One of the most sensitive enzyme system to detect P-5-P deficiency is kynureninase (L-kynurenine hydrolase; EC 3.7.1.3) that cleaves kynurenine to anthranilic acid and 3-hydroxykynurenine to 3-hydroxyanthranilic acid. Therefore an accumulation of kynurenine, 3-hydroxykynyrenine and also xan- o o thurenic acid in body fluids after tryptophan loading is the earliest used method for identification of P-5-P deficiency ( 10, 11) . By this method P-5-P deficiency was identified in 78% of cases from 61 CHD patient examined in this study and P-S-P deficiency was found in all groups of CHD patients (Fig.2) . Earlier studies have reported the normal range of homocysteiene in plasma or serum as to be S -15 !lmollL (18) . Serum homocysteine concentrations above 15 !lmol/L have been observed in 32.8% of our CHD patients. However the mean serum homocysteine concentration of 29 healthy individuals, aged 23-6S , examined in Riga was 8.9 ± 1.5 !lmollL (19) , which agrees with the data of literature too (20) . Therefore, an increased mean concentration of serum homocysteine has been observed in all groups of CHD patiens examined compared to the internal controls of this study (Fig. I ).
An albeit week but positive association was found between homocysteine and neopterin concentrations . A similar relationship between neopterin and homocysteine concentrations has been obtained earlier in patients without coronary heart diesase. Usually, insufficient dietary supply of vitamins such as folic acid, vitamins B6 and B 12 is considered as the major reason for hyperhomocysteinemia (20) . Neopterin concentrations are indicative for cellular (=Thl-type) immune activation and allow to estimate the degree of oxidative stress elicited during immune response (1,21). The fact that tetrahydrofolic acid is very susceptible to oxidation may become relevant under oxidative stress conditions. Thus, our data may suggest that immunologi- Fig.3 . Concentration (mean ± S.E.) of serum neopterin, homocysteine and kynurenine (at 3rd h after 30 mg Ltryptophan load) in CHD patients before PTCA due to 1st time stent implantation (hatched bars) and due to restenosis (black bars).*The changes are statistically significant (P <0.05).
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Rudzite V cr at : Serum neopterin, homocysteine and pyridoxal-5-phosphate in coronary heart disease J33 cally induced oxidative stress represents a major cause for endogenous folic acid depletion which results in hyperhomocysteinemia (22, 23) . Also P-5-P as an aldehyde is prone to be oxidized easily. Therefore, hyperhomocysteinemia and P-5-P deficiciency can be considered as a possible consequence of hyperconsumption of antioxidant vitamins during prolonged stat~s of immune activation, since immune activation cascades appear to be strongly involved in the pathogenesis of CHD.
In cases of restenosis both, further elevation of serum homocysteine concentration and further increase of serum kynurenine level after L-tryptophan loading, have been observed, if compared with the amounts found in patients before the 1 st stent implantation, while neopterin concentration remained unchanged (Fig.3) . It allows us to suggest that one of the basis for restenosis development in CHD patients is P-5-P deficiency followed by increased homocysteine concentrations in the blood. So, the normalization of these indices seems significant in the development and prevention of CHD as well as in the treatment of CHD patients.
